Use of a Polyclonal Antibody for the Determination of the Prognostic Value of c-erbB-2 Protein Over-Expression in Human Breast Cancer

Authors

  • Philippe Terrier Department of Pathology C, Institut Gustave-Roussy, Villejuif, France
  • Hélène Mouriesse Department of Medical Statistics, Institut Gustave-Roussy, Villejuif, France
  • Brigitte Loridon IRSC, Villejuif, France
  • Marianne Gotteland IRSC, Villejuif, France
  • Françoise May-Levin Department of Medicine, Institut Gustave-Roussy, Villejuif, France
  • Jean-Claude Delarue Department of Biological Chemistry, Institut Gustave-Roussy, Villejuif, France

DOI:

https://doi.org/10.3109/02841869609098475

Abstract

A rabbit-specific polyclonal antibody was obtained raised to a synthetic peptide corresponding to the 1238–1255 C-terminal predicted sequence of the c-erbB-2 protein. This antibody was used in an immunohistochemical procedure to detect the c-erbB-2 protein on a series of 88 paraffin-embedded human breast carcinomas. In 14/88 cases (16%) the c-erbB-2 protein was found to be overexpressed (immunohistochemical score > 1) with a good concordance with the previously determined mRNA level (79/88 cases: 90%). Prognostic significance of c-erbB-2 protein overexpression as detected by immuno-histochemistry was tested by the log-rank test. The relative risk of relapse is higher for patients with an immunohistochemical score > 1 (p = 0.00002). In a multivariate analysis the c-erbB-2 immunohistochemical score was the only powerful parameter (p < 1 · 10-3). In conclusion, this antibody seems to be a valuable tool in estimating the c-erbB-2 protein regarded in our series as a parameter able to identify a subgroup of operable breast cancer patients with a high risk of relapse.

Downloads

Download data is not yet available.

Downloads

Published

1996-01-01

How to Cite

Terrier, P., Mouriesse, H., Loridon, B., Gotteland, M., May-Levin, F., & Delarue, J.-C. (1996). Use of a Polyclonal Antibody for the Determination of the Prognostic Value of c-erbB-2 Protein Over-Expression in Human Breast Cancer. Acta Oncologica, 35(1), 23–30. https://doi.org/10.3109/02841869609098475